FibroBiologics Inc
FBLG
Company Profile
Business description
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Contact
455 E. Medical Center Boulevard
Suite 300
HoustonTX77598
USAT: +1 281 671-5150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Expense concerns for ASX best idea
Expense guidance changes short-term earnings but not long-term fundamentals.
stocks
Chart of the Week: Australian asset managers face structural pressure
Read the latest take from our analysts.
stocks
Going into earnings, is Alphabet a buy, a sell, or fairly valued?
From cloud computing growth to AI monetization, here’s what we’re looking for in Alphabet’s upcoming earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,236.90 | 6.40 | -0.07% |
| CAC 40 | 8,066.68 | 86.14 | -1.06% |
| DAX 40 | 24,822.79 | 71.65 | -0.29% |
| Dow JONES (US) | 49,015.60 | 12.19 | 0.02% |
| FTSE 100 | 10,154.43 | 53.37 | -0.52% |
| HKSE | 27,904.05 | 77.14 | 0.28% |
| NASDAQ | 23,857.45 | 40.35 | 0.17% |
| Nikkei 225 | 53,375.60 | 16.89 | 0.03% |
| NZX 50 Index | 13,348.61 | 64.26 | -0.48% |
| S&P 500 | 6,978.03 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,927.50 | 4.30 | 0.05% |
| SSE Composite Index | 4,157.98 | 6.75 | 0.16% |